Trial · NCT03803007
Acute Ischemic Stroke Interventional Study
NCT03803007, Phase 1, Phase 2, Completed, Acticor Biotech
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acute Ischemic Stroke Interventional Study. Trials, record NCT03803007. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03803007
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acute Ischemic Stroke Interventional Study
- NCT number
- NCT03803007
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 160 participants, actual
- Lead sponsor
- Acticor Biotech
- Conditions
- Acute Ischemic Stroke
- Interventions
- Intravenous ACT017 1000 mg, Intravenous Placebo
- First posted
- 2019-01-14
- Last updated
- 2021-10-06
- Other registries' IDs
- eudract:2018-002855-13
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Symptomatic intracranial haemorrhages | 24 hours | Number of participants experiencing a symptomatic haemorrhage defined by a secondary increase in National Institute Health Stroke Scale score by 4 points or greater, or death |
| Primary | Incidence of non-symptomatic intracranial haemorrhages | 24 hours | Non-symptomatic haemorrhages are those detected by Computerized Tomography scan |
| Secondary | Change from baseline of National Institute Health Stroke Scale score (7 minimum, 42 maximum), brain lesions and vessel recanalization | 24 hours | Absolute change from baseline of National Institute Health Stroke Scale score, change from baseline on brain lesions as assessed by Computerized Tomography scan or Magnetic Resonance Imaging or Magnetic Resonance Angiography, change from baseline on Recanalization as measured by the modified Thrombolysis In Cerebral Infarction score (0 minimum, 3 maximum) on Magnetic Resonance Angiography |
| Secondary | Change from baseline of National Institute Health Stroke Scale score (7 minimum, 42 maximum), brain lesions and vessel recanalization | 24 hours | Relative (%) change from baseline of National Institute Health Stroke Scale score, change from baseline on brain lesions as assessed by Computerized Tomography scan or Magnetic Resonance Imaging or Magnetic Resonance Angiography, change from baseline on Recanalization as measured by the modified Thrombolysis In Cerebral Infarction score (0 minimum, 3 maximum) on Magnetic Resonance Angiography |
| Secondary | Change from baseline of modified Ranking Scale score assessment | Day 90 | modified Ranking Scale score (0 minimum and 6 maximum): number of patients with favorable outcome (score 0-2) |
| Secondary | Change from baseline of modified Ranking Scale score assessment | Day 90 | modified Ranking Scale score (0 minimum and 6 maximum): percentage of patients with favorable outcome (score 0-2) |
| Secondary | Change from baseline on size of infarct zone | Day 7 | Change from baseline on size of infarct zone assessed by a central Magnetic Resonance Imaging review |
| Secondary | Change from baseline on vital signs | 6 hours, 24 hours, Day 7, Day 30 and Day 90 | Change from baseline on systolic and diastolic blood pressure |
| Secondary | Change from baseline on vital signs | 6 hours, 24 hours, Day 7, Day 30 and Day 90 | Change from baseline on heart rate |
| Secondary | Change from baseline on clinical laboratory assessments | Day 90 | Change from baseline on plasma haemoglobin level |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03803007
GET https://conductscience.org/api/trials/v1/NCT03803007/registered